Evidence map›Paper›PMID 26220749›Full record

ArticleJournal of hepatology2015

A cell culture system for distinguishing hepatitis C viruses with and without liver cancer-related mutations in the viral core gene.

Ahmed El-Shamy, Francis J Eng, Erin H Doyle, Arielle L Klepper, Xiaochen Sun, Angelo Sangiovanni, Massimo Iavarone, Massimo Colombo, Robert E Schwartz, Yujin Hoshida and 1 more

Open access · greenAbstract read
In one paragraph

Article in Journal of hepatology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Viral oncogenesis in cancer: from mechanisms to therapeutics.Signal transduction and targeted therapy · 2025
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 2 countries.

Ahmed El-ShamyDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Francis J EngDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Erin H DoyleDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Arielle L KlepperDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Xiaochen SunLiver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Angelo SangiovanniM. & A. Migliavacca Center for Liver Disease and 1st Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Massimo IavaroneM. & A. Migliavacca Center for Liver Disease and 1st Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Massimo ColomboM. & A. Migliavacca Center for Liver Disease and 1st Division of Gastroenterology, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico, University of Milan, Milan, Italy.
Robert E SchwartzDepartment of Medicine, Weill Cornell Medical College, Department of Physiology, Biophysics, and Systems Biology, Weill Cornell Medical College, New York, NY, USA.
Yujin HoshidaLiver Cancer Program, Tisch Cancer Institute, Division of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Andrea D BranchDivision of Liver Diseases, Department of Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: andrea.branch@mssm.edu.
Icahn School of Medicine at Mount Sinai · USUniversity of Milan · ITCornell University · USFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · IT

Funding

Optimizing Vitamin D Treatment in HIV/AIDS: An RCTR01DA031095 · NIDA · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRANCH, ANDREA D., DIETERICH, DOUGLAS THOMAS · 2010 to 2014
$3.3M
Molecular Prognostic Indicators in Liver Cirrhosis and CancerR01DK099558 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI HOSHIDA, YUJIN · 2013 to 2016
$2.6M
Modulation of HCV Gene ExpressionR01DK066939 · NIDDK · MOUNT SINAI SCHOOL OF MEDICINE OF NYU · PI BRANCH, ANDREA D. · 2004 to 2010
$2.0M
Clinical Outcomes and the HCV Core GeneR01DK090317 · NIDDK · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRANCH, ANDREA D. · 2010 to 2014
$2.0M
New Hepatocyte Model Systems to study Hepatitis B Virus InfectionK08DK101754 · NIDDK · WEILL MEDICAL COLL OF CORNELL UNIV · PI SCHWARTZ, ROBERT E · 2014 to 2018
$781k
Impact of species-specific host responses on restriction of hepatotropic virusesR21AI117213 · NIAID · PRINCETON UNIVERSITY · PI PLOSS, ALEXANDER, SCHWARTZ, ROBERT E · 2015 to 2016
$471k
HCV Strain Variation and HCCR21CA152514 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI BRANCH, ANDREA D. · 2011 to 2012
$406k
NCI NIH HHS R21 CA152514NIAID NIH HHS R21 AI117213NIDA NIH HHS R01 DA031095NIDDK NIH HHS 1K08DK101754NIDDK NIH HHS K08 DK101754NIDDK NIH HHS R01 DK066939NIDDK NIH HHS R01 DK090317NIDDK NIH HHS R01 DK099558
6 · The paper itself

Abstract

BACKGROUND &

aimsAlthough patients infected by genotype 1b hepatitis C virus (HCV) with Q(70) and/or M(91)core gene mutations have an almost five-fold increased risk of developing hepatocellular carcinoma (HCC) and increased insulin resistance, the absence of a suitable experimental system has precluded direct experimentation on the effects of these mutations on cellular gene expression.

methodsHuH7 cells were treated long-term with human serum to induce differentiation and to produce a model system for testing high-risk and control HCV. For clinical validation, profiles of infected cells were compared to each other and to those of liver biopsies of patients with early-stage HCV-related cirrhosis followed prospectively for up to 23 years (n=216).

resultsLong-term culture in human serum produced growth-arrested, hepatocyte-like cells whose gene profile overlapped significantly with that of primary human hepatocytes. High-risk (Q(70)/M(91)) and control (R(70)/L(91)) viruses had dramatically different effects on gene expression of these cells. The high-risk virus enhanced expression of pathways associated with cancer and type II diabetes, while the control virus enhanced pathways associated with oxidative phosphorylation. Of special clinical relevance, the transcriptome of cells replicating the high-risk virus correlated significantly with an HCC high-risk profile in patients (Bonferroni-corrected p=0.03), whereas no such association was observed for non-HCC-related clinical outcomes.

conclusionsThe cell-based system allowed direct head-to-head comparison of HCV variants, and provided experimental support for previous clinical data indicating an oncogenic effect of core gene mutations. This simple experimental system distinguished HCV variants and will enable future mechanistic analysis and exploration of interventional approaches.

Indexed as

Genes, ViralMutationCarcinoma, HepatocellularCell Culture TechniquesCell DifferentiationCell LineGenetic VariationGenotypeHepacivirusHepatitis B Core AntigensHepatitis C, ChronicHepatocytesHumansLiver CirrhosisLiver NeoplasmsOncogenesHepatitis B Core AntigensViral Core ProteinsCore-mutationsHCCHCVHuman serum

Identifiers

PMID26220749
PMCPMC4654634
OpenAlexW1017692166

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.